D Dimer Role in Coagulation Activation and Secondary Fibrinolysis
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, reposted from Horiba on LinkedIn:
”D dimer is an important biomarker of coagulation activation and secondary fibrinolysis that is routinely used to rule out venous thromboembolism (VTE), and to evaluate the risk of VTE recurrence, as well as the optimal duration of anticoagulant therapy.”
Horiba for Healthcare shared on LinkedIn:
”[Register now!] Free Online Workshop
D-Dimer: Diagnostic Challenges and Clinical Relevance
Thursday, October 16, 11–12 AM CEST
Register here.
This online workshop will focus on D dimer, a byproduct of the blood clotting and breakdown process that serves as a marker of ongoing coagulation and fibrinolysis.
The session will explore its clinical use in ruling out deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the inherent challenges—such as poor specificity, false positives, and difficulties in interpretation, especially in older patients or those with conditions like COVID-19 or cancer.
Participants will learn how to improve diagnostic accuracy and patient management through the use of clinical pretest probability assessments.
The workshop will also discuss the application of age-adjusted D dimer thresholds and the importance of confirmatory imaging in guiding clinical decisions.
Who should attend?
Healthcare professionals involved in D-dimer testing and thromboembolic disease management, such as pathologists, hemostasis lab scientists, acute care nurses, emergency physicians, hospitalists, hematologists, cardiologists, geriatricians, general practitioners, and trainees in related specialties.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly